Evrópusambandið - enska - EMA (European Medicines Agency)

novo nordisk a/s - insulin aspart, insulin degludec - diabetes mellitus - drugs used in diabetes - treatment of diabetes mellitus in adults, adolescents and children from the age of 2 years.

Singapúr - enska - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - insulin aspart; insulin degludec - injection, solution - insulin aspart 180nmol/ml; insulin degludec 420nmol/ml

Kanada - enska - Health Canada

sandoz canada incorporated - escitalopram (escitalopram oxalate) - tablet - 10mg - escitalopram (escitalopram oxalate) 10mg - selective-serotonin reuptake inhibitors

Kanada - enska - Health Canada

sun pharma canada inc - cyproterone acetate; ethinyl estradiol - tablet - 2mg; 0.035mg - cyproterone acetate 2mg; ethinyl estradiol 0.035mg - other miscellaneous therapeutic agents

Bandaríkin - enska - NLM (National Library of Medicine)

actavis pharma, inc. - drospirenone (unii: n295j34a25) (drospirenone - unii:n295j34a25) - drospirenone 3 mg

Bandaríkin - enska - NLM (National Library of Medicine)

watson pharma, inc. - drospirenone (unii: n295j34a25) (drospirenone - unii:n295j34a25) - drospirenone 3 mg

Bandaríkin - enska - NLM (National Library of Medicine)

pharmaceutics international, inc. (pii) - drospirenone (unii: n295j34a25) (drospirenone - unii:n295j34a25), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - drospirenone 3 mg - drospirenone and ethinyl estradiol tablets, usp 3 mg/0.02 mg are indicated for use by women to prevent pregnancy. drospirenone and ethinyl estradiol tablets, usp 3 mg/0.02 mg are indicated for the treatment of moderate acne vulgaris in women at least 14 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. drospirenone and ethinyl estradiol tablets, usp 3 mg/0.02 mg should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control. do not prescribe drospirenone and ethinyl estradiol tablets, usp 3 mg/0.02 mg to women who are known to have the following: - renal impairment - adrenal insufficiency - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)] have cerebrovascular disease [see warnin

Bandaríkin - enska - NLM (National Library of Medicine)

apotex corp. - drospirenone (unii: n295j34a25) (drospirenone - unii:n295j34a25), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - drospirenone 3 mg - drospirenone and ethinyl estradiol tablets are indicated for use by women to prevent pregnancy. do not prescribe drospirenone and ethinyl estradiol tablets to women who are known to have the following: - renal impairment - adrenal insufficiency - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)] have cerebrovascular disease [see warnings and precautions (5.1)] have coronary artery disease [see warnings and precautions (5.1)] have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1)] have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1)] have uncontrolled hypertension [see warnings and precautions (5.5)]

Ísrael - enska - Ministry of Health

bayer israel ltd - drospirenone; ethinylestradiol as betadex clathrate; levomefolate calcium; levomefolate calcium - film coated tablets - levomefolate calcium 0.451 mg; ethinylestradiol as betadex clathrate 0.02 mg; drospirenone 3 mg; levomefolate calcium 0.451 mg - estradiol, combinations - - oral contraception. - treatment of symptoms of premenstrual dysphoric disorder (pmdd ) in women who choose to use an oral contraceptive as their method of birth control.- treatment of moderate acne vulgaris in women at least 14 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. - in women who choose to use an oral contraceptive as their method of contraception, to raise folate levels for the purpose of reducing the risk of a neural tube defect in a pregnancy conceived while taking the product or shortly after discontinuing the product.

Armenía - enska - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

bayer weimar gmbh & co. kg - pink tablet-drospirenone, ethinyl estradiol, levomefolate (levomefolate calcium); light orange tablet-levomefolate (levomefolate calcium) - tablets film-coated - pink tablet-3mg+0,02mg+0,451mg